European Medicines Agency Adopts Positive Opinion for Merck's KEYTRUDA (pembrolizumab) for Six-Week Dosing Schedule Across All Current Monotherapy Indications
KENILWORTH, N.J.--(BUSINESS WIRE)--Mar 4, 2019--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for H…
